| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(19921115)70:10<2493::AID-CNCR2820701017>3.0.CO;2-K |
| P698 | PubMed publication ID | 1358427 |
| P2093 | author name string | T. Yamamoto | |
| K. Sato | |||
| M. Saito | |||
| T. Akiyama | |||
| S. Mori | |||
| K. Toyoshima | |||
| K. Terada | |||
| E. Okuhara | |||
| M. Moriyama | |||
| T. Watanuki | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder carcinoma | Q18556149 |
| tumor biomarker | Q66205818 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 2493-2498 | |
| P577 | publication date | 1992-11-01 | |
| 1992-11-15 | |||
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma | |
| P478 | volume | 70 |
| Q56538422 | A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0 |
| Q47773212 | A multivariate analysis of prognostic factors related to recurrence and progression of superficial bladder cancer |
| Q37281006 | Biomarkers in bladder cancer: present status and perspectives. |
| Q35543906 | Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics |
| Q36238822 | Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis |
| Q47929225 | Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma |
| Q34252516 | Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways |
| Q37186967 | Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer |
| Q38455324 | Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? |
| Q73174777 | Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer |
| Q92372449 | Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer |
| Q54594046 | Expression and function role of DNA methyltransferase 1 in human bladder cancer. |
| Q77380414 | Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma |
| Q41442987 | Growth factors in bladder cancer |
| Q64378443 | Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells |
| Q47794879 | HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder |
| Q54594744 | HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. |
| Q55090683 | HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. |
| Q50931074 | Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. |
| Q74226141 | Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2 |
| Q50064748 | Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer |
| Q41465655 | Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer |
| Q34630648 | Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer |
| Q41111921 | Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance |
| Q37243937 | Molecular pathogenesis of bladder cancer |
| Q81024663 | Molecular pathways in bladder cancer |
| Q72691766 | Molecular prognostic factors in bladder cancer |
| Q35175438 | Molecular prognostication in bladder cancer--a current perspective. |
| Q33851133 | Mutation of cell cycle regulators and their impact on superficial bladder cancer |
| Q77666818 | No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer |
| Q64907846 | Numeric aberrations of HER-2 and chromosome 17 detected by fluorescence in situ hybridization in urine-exfoliated cells from patients with urothelial carcinoma. |
| Q43660244 | Overexpression of HER-2/neu enhances the sensitivity of human bladder cancer cells to urinary isoflavones |
| Q35097989 | Overview of bladder cancer trials in the Cancer and Leukemia Group B. |
| Q59706184 | Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors |
| Q33554443 | Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer |
| Q35635508 | Pilot study of the clinical significance of serum and urinary her-2/neu protein in bladder cancer patients. |
| Q61450653 | Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder |
| Q40860524 | Prognostic factors in superficial bladder cancer |
| Q36363225 | Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers |
| Q71556929 | Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer |
| Q70887436 | Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer |
| Q40456228 | Recent advances in the molecular genetics of urogenital tumors |
| Q37704982 | Role of anti-Her-2 therapy in bladder carcinoma |
| Q82739755 | Role of biomarkers to predict outcomes and response to therapy |
| Q37290448 | Targeted therapies in the management of metastatic bladder cancer |
| Q36034067 | The clinical significance of HER2 protein amplification/expression in urinary bladder lesion |
| Q54143980 | The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. |
| Q38337192 | The route to personalized medicine in bladder cancer: where do we stand? |
| Q35173065 | Therapeutic approaches to bladder cancer: identifying targets and mechanisms |
| Q27691330 | Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model |
| Q35795474 | Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas |
| Q35172558 | Urothelial carcinomas: a focus on human epidermal receptors signaling |
| Q36230812 | Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma |
| Q33918737 | What we could do now: molecular pathology of bladder cancer |
| Q80716472 | [Prediction of tumor recurrence and progression of superficial bladder carcinoma using an artificial neural network] |
| Q72680108 | p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions |
Search more.